A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03787498 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Acute Myeloid Leukemia (AML)
Refractory Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)

Interventions

DRUG: PLX2853

Sponsor

Opna Bio LLC